Daisuke Kawauchi

Daisuke Kawauchi

Auto-generated profile, based on publicly available information

Daisuke Kawauchi

Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
TTTakahiro Tsuchiya
Takahiro Tsuchiya
DKDaisuke Kawauchi
Daisuke Kawauchi
MOMakoto Ohno
Makoto Ohno
YMYasuji Miyakita
Yasuji Miyakita
Masamichi TakahashiMasamichi Takahashi
Masamichi Takahashi
YNYOSHITAKA NARITA
YOSHITAKA NARITA
Isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM) is a highly aggressive brain tumor with a high recurrence rate despite adjuvant treatment. This study aimed to evaluate the risk factors for non-local recurrence of GBM. In the present study, we analyzed 104 GBMs with a single lesion (non-multifocal or multicentric). Univariate analysis revealed that subventricular zone (SVZ) involvement was significantly associated with non-local recurrence (hazard ratio [HR]: 2.09 [1.08–4.05]). Tumors in contact with the trigone of the lateral ventricle tended to develop subependymal dissemination (p = 0.008). Ventricular opening via surgery did not increase the risk of non-local recurrence in patients with SVZ involvement (p = 0.190). A systematic review was performed to investigate the risk of non-local recurrence, and 21 studies were identified. A meta-analysis of previous studies confirmed SVZ involvement (odds ratio [OR]: 1.30 [1.01–1.67]) and O-6-methylguanine DNA methyltransferase promoter methylation (OR: 1.55 [1.09–2.20]) as significant risk factors for local recurrence. A time-dependent meta-analysis revealed a significant association between SVZ involvement and dissemination (HR: 1.69 [1.09–2.63]), while no significant association was found for distant recurrence (HR: 1.29 [0.74–2.27]). Understanding SVZ involvement and specific tumor locations associated with non-local recurrence provides critical insights for the management of GBM.

1 July 2019 in World Neurosurgery
Verified
Journal Article
Closed access
SHSeiichiro Hirono
Seiichiro Hirono
DKDaisuke Kawauchi
Daisuke Kawauchi
MKMasayoshi Kobayashi
Masayoshi Kobayashi
RORyosuke Orimoto
Ryosuke Orimoto
SIShiro Ikegami
Shiro Ikegami
YIYasuo Iwadate
Yasuo Iwadate

24 February 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKasey R. Skinner
Kasey R. Skinner
TKTomoyuki Koga
Tomoyuki Koga
SMShunichiro Miki
Shunichiro Miki
RGRobert F. Gruener
Robert F. Gruener
FGFlorina-Nicoleta Grigore
Florina-Nicoleta Grigore
FFFrank B. Furnari
Frank B. Furnari
Diffuse midline glioma (DMG) is a leading cause of brain tumor death in children. In addition to hallmark H3.3K27M mutations, significant subsets also harbor alterations of other genes, such as TP53 and PDGFRA . Despite the prevalence of H3.3K27M, the results of clinical trials in DMG have been mixed, possibly due to the lack of models recapitulating its genetic heterogeneity. To address this gap, we developed human iPSC-derived tumor models harboring TP53 R248Q with or without heterozygous H3.3K27M and/or PDGFRA D842V overexpression. The combination of H3.3K27M and PDGFRA D842V resulted in more proliferative tumors when gene-edited neural progenitor (NP) cells were implanted into mouse brains compared to NP with either mutation alone. Transcriptomic comparison of tumors and their NP cells of origin identified conserved JAK/STAT pathway activation across genotypes as characteristic of malignant transformation. Conversely, integrated genome-wide epigenomic and transcriptomic analyses, as well as rational pharmacologic inhibition, revealed targetable vulnerabilities unique to the TP53 R248Q ; H3.3K27M; PDGFRA D842V tumors and related to their aggressive growth phenotype. These include AREG -mediated cell cycle control, altered metabolism, and vulnerability to combination ONC201/trametinib treatment. Taken together, these data suggest that cooperation between H3.3K27M and PDGFRA influences tumor biology, underscoring the need for better molecular stratification in DMG clinical trials.

2 August 2023 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
DKDaisuke Kawauchi
Daisuke Kawauchi
MOMakoto Ohno
Makoto Ohno
YMYasuji Miyakita
Yasuji Miyakita
MTMasamichi Takahashi
Masamichi Takahashi
SYShunsuke Yanagisawa
Shunsuke Yanagisawa
YNYOSHITAKA NARITA
YOSHITAKA NARITA
The neurological status of glioblastoma patients rapidly deteriorates. We recently demonstrated that early diagnosis and surgery within 3 weeks from the initial symptoms are associated with improved survival. While glioblastoma is a semi-urgent disease, the prehospital behaviors and clinical outcomes of glioblastoma patients are poorly understood. We aimed to disclose how prehospital patient behavior influences the clinical outcomes of glioblastoma patients. Isocitrate dehydrogenase-wildtype glioblastoma patients treated at our institution between January 2010 and December 2019 were reviewed. Patients were divided into two groups, neurosurgeon and non-neurosurgeon groups, based on the primary doctor whom patients sought for an initial evaluation. Patient demographics and prognoses were examined. Of 170 patients, 109 and 61 were classified into the neurosurgeon and non-neurosurgeon groups, respectively. The median age of neurosurgeon group was significantly younger than the non-neurosurgeon group (61 vs. 69 years old, P = 0.019) and in better performance status (preoperative Karnofsky performance status scores |$\ge$|80: 72.5 vs. 55.7%, P = 0.027). The neurosurgeon group exhibited a significantly shorter duration from the first hospital visit to the first surgery than the non-neurosurgeon group (18 vs. 29 days, P < 0.0001). Furthermore, the overall survival of the neurosurgeon group was significantly more prolonged than that of the non-neurosurgeon group (22.9 vs. 14.0 months, P = 0.038). Seeking an initial evaluation by a neurosurgeon was potentially associated with prolonged survival in glioblastoma patients. A short duration from the first hospital visit to the first surgery is essential in enhancing glioblastoma patient prognosis.

20 August 2025 in International Cancer Conference Journal
Verified
Journal Article
Closed access
PDF file
DKDaisuke Kawauchi
Daisuke Kawauchi
YMYasuji Miyakita
Yasuji Miyakita
YKYuki Kawaguchi
Yuki Kawaguchi
MOMakoto Ohno
Makoto Ohno
SYShunsuke Yanagisawa
Shunsuke Yanagisawa
YNYoshitaka Narita
Yoshitaka Narita

1 September 2019 in World Neurosurgery
Verified
Journal Article
Closed access
DKDaisuke Kawauchi
Daisuke Kawauchi
YHYoshinori Higuchi
Yoshinori Higuchi
SIShiro Ikegami
Shiro Ikegami
AAAkihiko Adachi
Akihiko Adachi
KOKo Ozaki
Ko Ozaki
YIYasuo Iwadate
Yasuo Iwadate